Figures reflect market struggles for each of the firms and the industry as a whole.
The first Cavitron model 7001 was commercialized in 1970, and an estimated 200,000 ultrasonic phaco (USP) machines have been purchased since then by cataract surgeons globally.
Sessions include updates on Alcon PanOptix trifocal IOL and Abbott Symfony extended depth of focus lens.
The drug is priced at a 25 percent discount to the Roche/Novartis VEGF inhibitor.
David Pyott, former CEO of Allergan, and Howard Schiller, former CFO of Valeant, testified on the events that played out in 2014.
Sale of generic assets to Teva for $40.5 billion gives the Dublin-based firm a cash infusion.
Three-judge panel recognized firm’s claim that the new formulation offered unexpected properties and was sufficiently different from previous inventions.
Sales for the dry eye treatment totaled $1.08 billion in 2014.
In July, the stock price jumped 200 percent, as the company reported late-stage plans for trabodenoson.
Luminate would challenge ThromboGenics’ Jetrea, which has struggled due to lack of demand.
Researchers say proposed FDA time restriction on using compounded Avastin may have unintended consequences.
Agency says DME affects around 189,000 people with diabetes in the UK.
Previous "scoreboard" model is unrealistic, the scientists said.
The study is being conducted at Manchester Royal Eye Hospital, where surgeons hope to enroll another four patients.
The Opternative exam is accessed via a desktop computer and requires an android device to answer questions.
The newest VEGF inhibitor has made significant gains since Q3-2014, according to Market Scope surveys.
The device allows an ophthalmic surgeon to inject stents into multiple trabecular meshwork locations through a single corneal entry point.
The company plans to roll out the VisionFit Wearable Adaptive Refractor at the 2015 ESCRS meeting in Barcelona.
You are not currently logged in.
©2018 Market Scope
Lost your Password